Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/34709 |
Resumo: | Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment. |
id |
UNIFEI_e1da9985127d1b78cb714714bba95400 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/34709 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study Calidad de vida relacionada con la salud de pacientes con mieloma múltiple después del tratamiento de primera línea: resultados de un estudio de cohorte prospectivoQualidade de vida relacionada à saúde de pacientes com mieloma múltiplo após o tratamento de primeira linha: resultados de um estudo de coorte prospectiva Mieloma MúltipleCalidad de VidaTalidomidaBortezomibEnfermedades del Sistema Nervioso Periférico.Mieloma múltiploQualidade de vidaTalidomidaBortezomibeNeuropatias periféricas.Multiple MyelomaQuality of lifeThalidomideBortezomibPeripheral neuropathy.Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment.Objetivo: El objetivo fue evaluar si hubo una mejora o empeoramiento en la calidad de vida relacionada con la salud (CVRS) de pacientes con mieloma múltiple (MM) y factores asociados a la CVRS después de 12 meses de tratamiento. Métodos: Se realizó un estudio de cohorte prospectivo con pacientes con MM en tratamiento de primera línea en servicios oncohematológicos de Brasil. Se obtuvieron variables clínicas, sociodemográficas y CVRS a través de entrevistas y revisión de historias médicas. La CVRS y la neuropatía periférica (NP) se recogieron mediante instrumentos validados. Se compararon las puntuaciones medianas de la CVRS obtenidas de las entrevistas iniciales y de seguimiento. Se midió la mejora o empeoramiento de la CVRS y la asociación con variables. Resultados: Treinta y tres pacientes completaron el seguimiento, con ISS III (25,0%), polifarmacia (72,2%), usando talidomida+bortezomib como primera línea (19,4%), y una mediana de edad de 66,5 años. La puntuación resumida, las escalas funcionales y de síntomas y la perspectiva futura mejoraron entre períodos (p<0,05). Los pacientes en polifarmacia, con NP grave e ISS III presentaron empeoramiento de la CVRS; los pacientes más jóvenes mejoraron y los pacientes mayores empeoraron en CVRS (p<0,05). Conclusiones: El tratamiento de primera línea mejoró la CVRS de los pacientes en las siguientes escalas QLQ-C30: puntuación resumida, escala funcional y emocional, fatiga, dolor y estreñimiento; y en QLQ-MY20, la perspectiva de futuro ha mejorado. Nuestro estudio muestra la importancia de utilizar los resultados informados por los pacientes durante el tratamiento del MM.Objetivo: O objetivo foi avaliar se houve melhora ou piora da qualidade de vida relacionada à saúde (QVRS) de pacientes com mieloma múltiplo (MM) e fatores associados à QVRS após 12 meses de tratamento. Métodos: Realizou-se estudo de coorte prospectiva com pacientes com MM em tratamento de primeira linha em serviços de saúde de onco-hematologia públicos e privado no Brasil. QVRS, variáveis sociodemográficas e clínicas foram obtidas por meio de entrevistas e revisão de prontuários. QVRS e neuropatia periférica (NP) foram coletadas por meio de instrumentos validados (QLQ-C30, QLQ-MY20, CINQ). As medianas dos escores de QVRS, obtidos nas entrevistas basais e de seguimento, foram comparadas. Os escores medianos de QVRS no seguimento foram comparados por variáveis. A melhora ou piora da QVRS e a associação com variáveis foram mensuradas. Resultados: Trinta e três pacientes completaram o seguimento, com ISS III (25,0 %), polifarmácia (72,2 %), em uso de talidomida+bortezomibe como primeira linha (19,4 %), e idade mediana de 66,5 anos. O Escore sumarizado, escalas Funcionais e de Sintomas e Perspectiva Futura melhoraram entre os períodos (p<0,05). Pacientes em polifarmácia, com NP grave e ISS III apresentaram piora da QVRS; pacientes mais jovens tiveram melhora e pacientes mais velhos pioraram na QVRS (p<0,05). Conclusões: O tratamento de primeira linha melhorou a QVRS dos pacientes nas seguintes escalas QLQ-C30: escore sumarizado, escala funcional, escala emocional, fadiga, dor e constipação; e no QLQ-MY20, a perspectiva futura melhorou. Nosso estudo mostra a importância de usar resultados relatados pelo paciente durante o tratamento do MM.Research, Society and Development2022-09-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3470910.33448/rsd-v11i12.34709Research, Society and Development; Vol. 11 No. 12; e351111234709Research, Society and Development; Vol. 11 Núm. 12; e351111234709Research, Society and Development; v. 11 n. 12; e3511112347092525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/34709/29162Copyright (c) 2022 Paula Lana de Miranda Drummond; Roberta Márcia Marques dos Santos; Adriano Max Moreira Reis; Jéssica Soares Malta; Lívia Pena Silveira; Iwyson Henrique Fernandes da Costa; Bárbara Soares Diniz Marques; Roberta Oliveira de Paula e Silva; Evandro Maranhão Fagundes; Enrico Antônio Colosimo; Cristiane Aparecida Menezes de Páduahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessDrummond, Paula Lana de Miranda Santos, Roberta Márcia Marques dos Reis, Adriano Max MoreiraMalta, Jéssica Soares Silveira, Lívia Pena Costa, Iwyson Henrique Fernandes da Marques, Bárbara Soares Diniz Silva, Roberta Oliveira de Paula e Fagundes, Evandro Maranhão Colosimo, Enrico AntônioPádua, Cristiane Aparecida Menezes de 2022-09-26T11:56:08Zoai:ojs.pkp.sfu.ca:article/34709Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:49:54.096327Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study Calidad de vida relacionada con la salud de pacientes con mieloma múltiple después del tratamiento de primera línea: resultados de un estudio de cohorte prospectivo Qualidade de vida relacionada à saúde de pacientes com mieloma múltiplo após o tratamento de primeira linha: resultados de um estudo de coorte prospectiva |
title |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study |
spellingShingle |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study Drummond, Paula Lana de Miranda Mieloma Múltiple Calidad de Vida Talidomida Bortezomib Enfermedades del Sistema Nervioso Periférico. Mieloma múltiplo Qualidade de vida Talidomida Bortezomibe Neuropatias periféricas. Multiple Myeloma Quality of life Thalidomide Bortezomib Peripheral neuropathy. |
title_short |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study |
title_full |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study |
title_fullStr |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study |
title_full_unstemmed |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study |
title_sort |
Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study |
author |
Drummond, Paula Lana de Miranda |
author_facet |
Drummond, Paula Lana de Miranda Santos, Roberta Márcia Marques dos Reis, Adriano Max Moreira Malta, Jéssica Soares Silveira, Lívia Pena Costa, Iwyson Henrique Fernandes da Marques, Bárbara Soares Diniz Silva, Roberta Oliveira de Paula e Fagundes, Evandro Maranhão Colosimo, Enrico Antônio Pádua, Cristiane Aparecida Menezes de |
author_role |
author |
author2 |
Santos, Roberta Márcia Marques dos Reis, Adriano Max Moreira Malta, Jéssica Soares Silveira, Lívia Pena Costa, Iwyson Henrique Fernandes da Marques, Bárbara Soares Diniz Silva, Roberta Oliveira de Paula e Fagundes, Evandro Maranhão Colosimo, Enrico Antônio Pádua, Cristiane Aparecida Menezes de |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Drummond, Paula Lana de Miranda Santos, Roberta Márcia Marques dos Reis, Adriano Max Moreira Malta, Jéssica Soares Silveira, Lívia Pena Costa, Iwyson Henrique Fernandes da Marques, Bárbara Soares Diniz Silva, Roberta Oliveira de Paula e Fagundes, Evandro Maranhão Colosimo, Enrico Antônio Pádua, Cristiane Aparecida Menezes de |
dc.subject.por.fl_str_mv |
Mieloma Múltiple Calidad de Vida Talidomida Bortezomib Enfermedades del Sistema Nervioso Periférico. Mieloma múltiplo Qualidade de vida Talidomida Bortezomibe Neuropatias periféricas. Multiple Myeloma Quality of life Thalidomide Bortezomib Peripheral neuropathy. |
topic |
Mieloma Múltiple Calidad de Vida Talidomida Bortezomib Enfermedades del Sistema Nervioso Periférico. Mieloma múltiplo Qualidade de vida Talidomida Bortezomibe Neuropatias periféricas. Multiple Myeloma Quality of life Thalidomide Bortezomib Peripheral neuropathy. |
description |
Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09-17 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/34709 10.33448/rsd-v11i12.34709 |
url |
https://rsdjournal.org/index.php/rsd/article/view/34709 |
identifier_str_mv |
10.33448/rsd-v11i12.34709 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/34709/29162 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 12; e351111234709 Research, Society and Development; Vol. 11 Núm. 12; e351111234709 Research, Society and Development; v. 11 n. 12; e351111234709 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052723582992384 |